Exact Sciences (STU:EXK) Retained Earnings : €-3,293 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Exact Sciences Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Exact Sciences's retained earnings for the quarter that ended in Mar. 2024 was €-3,293 Mil.

Exact Sciences's quarterly retained earnings increased from Sep. 2023 (€-3,204 Mil) to Dec. 2023 (€-3,181 Mil) but then declined from Dec. 2023 (€-3,181 Mil) to Mar. 2024 (€-3,293 Mil).

Exact Sciences's annual retained earnings declined from Dec. 2021 (€-2,338 Mil) to Dec. 2022 (€-3,082 Mil) and declined from Dec. 2022 (€-3,082 Mil) to Dec. 2023 (€-3,181 Mil).

Exact Sciences Retained Earnings Historical Data

The historical data trend for Exact Sciences's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Sciences Retained Earnings Chart

Exact Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-1,007.78

-1,681.73

-2,337.75

-3,082.19

-3,181.23

Exact Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Retained Earnings	Get a 7-Day Free Trial															-3,118.79	-3,156.85	-3,203.99	-3,181.23	-3,293.05

Exact Sciences Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Exact Sciences (STU:EXK) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Exact Sciences (STU:EXK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (STU:EXK) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

EXAS:USA

Address

5505 Endeavor Lane, Madison, WI, USA, 53719

Website

https://www.exactsciences.com

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.